Paveena Yamanont

  • M.Sc. (Pharmacology) Chulalongkorn University, Thailand
Current Research
  • Lipid oxidation in thalassemia
  1. Rodrat S, Yamanont P, Tankanitlert J, Chantraraksri U, Fucharoen S, Morales NP. Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients. Pharmacology. 2012;90(1-2):88-94.
  2. Limenta LM, Jirasomprasert T, Jittangprasert P, Wilairat P, Yamanont P, Chantharaksri U, Fucharoen S, Morales NP. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status. Clin Pharmacokinet. 2011;50(1):41-50.
  3. Morales NP, Yamanont P, Jirasomprasert T, Wilairat P, Chantharaksri U, Chuncharunee S, et al. Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers.Int J Clin Pharmacol Ther. 2009;47(5):358-64.
  4. Jirasomprasert T, Morales NP, Limenta LM, Sirijaroonwong S, Yamanont P, Wilairat P, et al. Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in β-thalassemia. Free Radic Res. 2009;43(5):485-91.
  5. Morales NP, Charlermchoung C, Luechapudiporn R, Yamanont P, Fucharoen S, Chantharaksri U. Lipid fluidity at different regions in LDL and HDL of β-thalassemia/Hb E patients. Biochem Biophys Res Commun. 2006;350(3):698-703.
  6. Sibmooh N, Yamanont P, Krudsood S, Leowattana W, Brittenham G, Looareesuwan S, et al. Increased fluidity and oxidation of malarial lipoproteins: relation with severity and induction of endothelial expression of adhesion molecules. Lipids Health Dis. 2004;3:15.